Interviews

In part 2, Rosa Novo discusses how employers can expand access to cancer screening and why they need a greater voice in shaping cancer care.

AI could ease oncology's drug development "traffic jam," while biomarker subsetting drives more personalized cancer care, David Spigel, MD, says.

Amanda Green, MPH, discusses how employers can improve benefit awareness, care navigation, cancer prevention, and cost strategies.

Debra Patt, MD, PhD, MBA, MPH, discusses how AI can streamline prior authorization and revenue cycle workflows in community oncology.

Chester Good, MD, MPH, shares data and strategies used by UPMC to evaluate value-based contracting in specialty pharmacy.

Advanced primary care, return-to-work support, and survivorship follow-up are key employer cancer strategies, said Karen van Caulil, PhD.

Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.

Community oncology faces high costs and staffing hurdles for trials; Lucio N. Gordan, MD, urges pragmatic designs matching real-world patients.

In part 2, David Johnson, MD, MPH, discusses how real-time data can sustain gold carding, ease prior authorization burden, and ensure accountability.

Liquid biopsy and at-home phlebotomy are closing precision medicine access gaps nationwide, though tissue remains the gold standard.

Irfana Lakada, PharmD, CSP, explains why onboarding may be the wrong time to screen for social needs and why rescreening matters.

Jesse Dresser explains how federal PBM reform, a new CMS RFI, and FTC settlements could reshape specialty pharmacy contracts and pay from 2027.

Madhav R. Seshadri, MD, speaks on CLL's shift toward fixed-duration, MRD-guided regimens, MRD testing barriers, and open questions on drug sequencing.

Karen van Caulil, PhD, explained why employers evaluating cancer care weigh timely access, quality, and equity alongside cost.

Stephen "Fred" Divers, MD, discusses how COA study data push back on payer bias and support community oncology's long-term sustainability.

Overlapping COVID-19 and flu symptoms make diagnosis hard, says Trinity Health's Tammy Lundstrom, who outlines prevention and vaccine guidance.

David Johnson, MD, MPH, discusses how payer data can reduce low-value cancer care and steer patients to supportive services and cost-efficient sites.

Robust survivorship programs exist at some institutions, but needs vary widely from patient to patient, explains Bhavana Bhatnagar, DO.

Stephen “Fred” Divers, MD, discusses findings showing community oncology delivers outcomes comparable with academic care for breast cancer and NSCLC.

Stephen "Fred" Divers, MD, previews PCOC 2026, including his session on the Oncology Care Index and the gap in AI adoption in oncology.

For Bhavana Bhatnagar, DO, delivering bispecifics and CAR T-cell therapy requires infrastructure, education, SOPs, and experienced academic colleagues.

Christine Pfaff, RPh, MBA, discusses barriers to community cellular therapy delivery and the need for new business models and payer collaboration.

Within polycythemia vera, patients can be iron deficient while continuing to produce too many red blood cells, explains Andrew Kuykendall, MD.

However, the risk of these rare cancers is not enough to dissuade prescribing CAR T-cell therapy for CLL, explains Kerry Rogers, MD, The James.

Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.

Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.

J&J's Oncology Care Index finds a systems problem, not a confidence gap, in community oncology, Mahadi Baig, MD, says.

Bundled payment models offer employers and community oncology practices greater cost predictability while improving patient access, Baird said.